Axtell spent 15 hours paddleboarding the gap between Bimini and Lake Worth Beach. Although stormy and hot weather made it ...

BETHESDA, Md. (July 16, 2025) – Today, the Cystic Fibrosis Foundation announced an additional investment of up to $24 million ...

NHS patients in England with cystic fibrosis will be among the first in Europe to access a new treatment for their condition, ...

Reimbursement authority NICE has backed routine NHS use of Vertex's once-daily triple therapy Alyftrek ...

Charles Kim Haskell told Newsweek he once thought he wouldn't live beyond his teenage years, but, at 31, he is enjoying his life.

Hundreds of cystic fibrosis patients become eligible for ‘life-changing’ therapy - Some people with the rarest forms of the ...

Expanded funding builds on the initial agreement to accelerate development of Prime Editors for Cystic Fibrosis (CF) -- -- Prime Medicin ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

Vertex Pharmaceuticals (VRTX) experienced a 4% price increase over the past month, coinciding with crucial developments in their portfolio. The recent advancement with NHS England's reimbursement ...

Alfie Coe, 13, from Terrington St Clement, will be running 3km daily during his school summer holidays to raise money for the ...

NHS England » NHS to roll-out new ‘triple combination’ therapy for hundreds of children and adults with cystic fibrosis ...

Alyftrek (vanzacaftor–tezacaftor–deutivacaftor), made by Vertex, represents the latest advance in CFTR modulator treatments that are transforming cystic fibrosis care by targeting the underlying cause ...